His case illustrates the diffi culty of diagnosing coronary artery disease in patients who have no symptoms of it. For many, the initial presentation is myocardial infarction or death. Until recently, there was no reliable way to diagnose subclinical coronary artery disease other than angiography, and there is still no way to rule it out. As a result, physicians have concentrated less on diagnosing subclinical disease and more on assessing the risk of myocardial infarction.
■ ASSESSING RISK
The risk factors for coronary artery disease (age, male sex, smoking, hypertension, and cholesterol) have been well known for half a century. By combining risk factors with the appropriate weighting, it is possible to predict an individual's risk of a myocardial infarction.
In 2013, the American College of Cardiology/American Heart Association (ACC/ AHA) guidelines applied this risk-based approach to prescribing statins for primary prevention. 2 Instead of focusing on low-density lipoprotein cholesterol concentration, which by itself is a poor predictor of myocardial infarction, they recommended using the Pooled Cohort Equation 3 to determine the risk of a cardiovascular event within 10 years. For patients at high risk (> 7.5%), the benefi ts of a statin generally outweigh the harms. For those at low risk (< 5%), the opposite is true. For patients in between, there is room for shared decision-making.
Debate has focused on the predictive accuracy of the equation, the threshold for treatment, and the fact that almost all men over 60 qualify for treatment. 4 These objections stem from the focus on risk rather than on diagnosis of the underlying disease.
Because one-third of "high-risk" patients never develop cardiovascular disease, 5 the risk-based approach necessitates overtreatment. Those without disease cannot benefi t from treatment but nonetheless suffer its side effects, cost, and inconvenience. Raising treatment thresholds (eg, treating only patients whose 10-year risk exceeds 10%) improves the ratio of patients with disease to those without but also misses diseased patients who have few risk factors. "Low risk" is not "no risk." these patients, calcium scoring could reclassify most as being at high or low risk, helping to clarify whether statins are indicated. However, only 12% of patients fall into this category. 7 What about patients at higher risk? Could they be reclassifi ed as being at low risk if their calcium score was 0?
■ TESTING FOR DISEASE IN THOSE AT INTERMEDIATE RISK
8 Conversely, could some low-risk patients discover that they are at high risk and perhaps take action?
The ACC/AHA guidelines recommend against calcium scoring in these circumstances. One concern was that calcium scoring had not been tested with the Pooled Cohort Equation. Another concern related to cost and radiation exposure, but as Parikh et al point out, the cost has now fallen to less than $100, and radiation exposure is similar to that with mammography.
■ SHOULD WE TEST PATIENTS AT HIGH OR LOW RISK?
Who, then, should we test? For patients at high or low risk according to the Pooled Cohort Equation, 2 questions determine whether calcium scoring is warranted: how much would an extremely high or low score (ie, 0 or > 400) change the risk of an event, and how likely is an extreme score? The fi rst question relates to the usefulness of the test, the second to its cost-effectiveness. If even an extreme score cannot move a patient's risk into or out of the treatment range, then testing is unwarranted. At the same time, if few patients have an extreme score, then cost per test that changes practice will be high.
Because calcium scoring is a direct test for disease, it is extremely predictive. When added to risk-factor models, it substantially improves discrimination 9 and exhibits excellent calibration. 10 This is true whether the outcome is a major cardiovascular event or death from any cause.
But the calcium score is not strong enough to override all other risk factors. A patient with a predicted 10-year risk of 18% according to the Pooled Cohort Equation and a calcium score of 0 could be reclassifi ed as being at low risk, but a patient with a 10-year predicted risk of 35% could not. The same is true for patients at low risk. A patient with a 4% risk and a calcium score higher than 400 would be reclassifi ed as being at high risk, but not a patient with a 1% risk.
Extreme calcium scores are common, especially in patients at high risk. In the MultiEthnic Study of Atherosclerosis (MESA) cohort, 45% of patients with a 10-year predicted risk of 7.5% to 20% had a calcium score of 0, reclassifying them into the low-risk category.
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Even if the predicted risk was greater than 20%, 1 in 4 patients had a score of 0. In contrast, if the 10-year predicted risk was below 5%, one-fi fth of patients had a calcium score greater than 0, but only 4% had a score greater than 100.
Nevertheless, patients in the low-risk category whose baseline risk is close to 5% may wish to undergo calcium scoring, because a positive test opens the door to a potentially lifesaving treatment. In general, the closer patients are to the treatment threshold, the more likely they are to be reclassifi ed by calcium scoring.
The Society for Cardiovascular Computed Tomography currently recommends coronary artery calcium scoring for patients whose 10-year risk is between 5% and 20%. 12 These numbers are easy to remember and a reasonable approximation of the number of patients likely to benefi t from testing.
■ COMBINING CALCIUM SCORING WITH TRADITIONAL RISK FACTORS
Primary care physicians interested in more exact personalized medicine can use a risk calculator derived from the MESA cohort. 13 Based on 10-year outcomes for 6,814 participants, Blaha et al 8 derived and validated this riskprediction tool incorporating all the elements of the Pooled Cohort Equation in addition to family history, race, and calcium score.
The tool offered good discrimination and calibration when validated against 2 external cohorts (the Heinz Nixdorf Recall Study and the Dallas Heart Study). 10 The C statistics were 0.78 and 0.82, with 10-year risk predicted by the tool within half a percent of the observed event rate in each cohort.
The online calculator displays the 10-year risk based on risk factors alone or including a calcium score, allowing the clinician to gauge Since one-third of 'high-risk' patients never develop cardiovascular disease, the risk-based approach necessitates overtreatment ROTHBERG the value of testing. For example, a 70-yearold nonsmoking white man with a total cholesterol level of 240 mg/dL, high-density lipoprotein cholesterol 40 mg/dL, and systolic blood pressure 130 mm Hg on amlodipine has a 15.2% 10-year risk (well above the 7.5% threshold for statin therapy). However, if his calcium score is 0, his risk falls to 4.3% (well below the threshold). Sharing such information with patients could help them to decide whether to undergo coronary artery calcium scoring.
Ultimately, the decision to take a statin for primary prevention of coronary artery disease is a personal one. It involves weighing risks, benefi ts, and preferences. Physicians can facilitate the process by providing information and guidance. Patients are best served by having the most accurate information. In many cases, that information should include calcium scoring. ■ ■ REFERENCES
